NO20013146L - Means for the treatment of visual cell dysfunction - Google Patents

Means for the treatment of visual cell dysfunction

Info

Publication number
NO20013146L
NO20013146L NO20013146A NO20013146A NO20013146L NO 20013146 L NO20013146 L NO 20013146L NO 20013146 A NO20013146 A NO 20013146A NO 20013146 A NO20013146 A NO 20013146A NO 20013146 L NO20013146 L NO 20013146L
Authority
NO
Norway
Prior art keywords
treatment
cell dysfunction
visual cell
visual
dysfunction
Prior art date
Application number
NO20013146A
Other languages
Norwegian (no)
Other versions
NO20013146D0 (en
Inventor
Ryuji Ueno
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of NO20013146D0 publication Critical patent/NO20013146D0/en
Publication of NO20013146L publication Critical patent/NO20013146L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20013146A 1998-12-24 2001-06-22 Means for the treatment of visual cell dysfunction NO20013146L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11393998P 1998-12-24 1998-12-24
PCT/JP1999/007161 WO2000038703A1 (en) 1998-12-24 1999-12-20 Agent for treating visual cell function disorder

Publications (2)

Publication Number Publication Date
NO20013146D0 NO20013146D0 (en) 2001-06-22
NO20013146L true NO20013146L (en) 2001-08-20

Family

ID=22352417

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013146A NO20013146L (en) 1998-12-24 2001-06-22 Means for the treatment of visual cell dysfunction

Country Status (13)

Country Link
EP (1) EP1140134A1 (en)
JP (1) JP2002542150A (en)
KR (1) KR20010099928A (en)
CN (1) CN1224420C (en)
AR (1) AR022017A1 (en)
AU (1) AU781049B2 (en)
BR (1) BR9917113A (en)
CA (1) CA2356382A1 (en)
MX (1) MXPA01006449A (en)
NO (1) NO20013146L (en)
NZ (1) NZ513111A (en)
TW (1) TW546145B (en)
WO (1) WO2000038703A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
WO2003061519A2 (en) 2002-01-18 2003-07-31 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
ES2428354T3 (en) 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamycin for use in the inhibition or prevention of choroidal neovascularization
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
AU2006213588B2 (en) 2005-02-09 2011-11-17 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions
WO2007019427A2 (en) * 2005-08-08 2007-02-15 Massachusetts Eye & Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
CN103127100A (en) 2006-03-23 2013-06-05 参天制药株式会社 Formulation and method for vascular permeability-related diseases or conditions
CN112912107A (en) * 2018-10-15 2021-06-04 国立大学法人大阪大学 Drug for improvement or prevention of symptoms associated with retina and/or photoreceptor, and method for screening substance for improvement or prevention of symptoms associated with retina and/or photoreceptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69124380T2 (en) * 1990-08-23 1997-08-14 Univ New York METHOD AND COMPOSITIONS FOR THE TREATMENT BY T-CELL-MEDIATED DISEASES
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
JP2002511868A (en) * 1997-06-30 2002-04-16 アラーガン・セイルズ・インコーポレイテッド Calcium blockers for treating proliferative vitreoretinopathy
CZ287497B6 (en) * 1997-12-30 2000-12-13 Galena, A. S. Topic eye preparations containing immunosuppressive substances
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders

Also Published As

Publication number Publication date
CA2356382A1 (en) 2000-07-06
NO20013146D0 (en) 2001-06-22
MXPA01006449A (en) 2002-04-24
JP2002542150A (en) 2002-12-10
CN1352565A (en) 2002-06-05
WO2000038703A1 (en) 2000-07-06
AU781049B2 (en) 2005-05-05
NZ513111A (en) 2003-10-31
TW546145B (en) 2003-08-11
KR20010099928A (en) 2001-11-09
CN1224420C (en) 2005-10-26
AU1690600A (en) 2000-07-31
AR022017A1 (en) 2002-09-04
BR9917113A (en) 2001-10-23
EP1140134A1 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
IS2494B (en) Use of morpholinol for the treatment of sexual dysfunction
DE60020327D1 (en) The water treatment unit
NO20012160D0 (en) Device for the treatment of macular degeneration
EE200200710A (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
DE60019556D1 (en) 2-AMINO-BENZOXAZINE DERIVATIVES FOR THE TREATMENT OF FATIBILITY
NO952749L (en) Water treatment agent
EA199900336A3 (en) APPARATUS FOR WATER TREATMENT WITH INDICATOR OF THE DEGREE OF MEANS OF CLEANING
DK0965566T3 (en) Process for the treatment of organic wastewater
NO20010456D0 (en) Triazolopyridines for the treatment of thrombosis problems
NO20013146D0 (en) Means for the treatment of visual cell dysfunction
NO20012106L (en) Means for the treatment of disorders of bone metabolism
NO20013596L (en) Sludge treatment
AU5509099A (en) Pyridinones for the treatment of sexual dysfunction
AU4774599A (en) Process for the treatment of waste water
DK1054868T3 (en) Substituted pyridinoarylpiperazines suitable for the treatment of prostate hyperplasia
AU3814599A (en) Use of erythropoietin for the treatment of haemochromatoses
NO20011892L (en) 3-tetrahydropyridin-4-yl indoles for the treatment of psychotic disorders
NO20003481D0 (en) Procedure for the treatment of COPD
NO20012612D0 (en) Isonipecotamides for the treatment of integrin-mediated disorders
AU3843600A (en) Bath equipped with water vibrator and therapeutic method using the same
NO20012616D0 (en) Means for the treatment of erectile malfunction
GB2332849B (en) Apparatus for the treatment of soil
FI981803A0 (en) Method for preventing the formation of precipitates
DE50015962D1 (en) System for the treatment of drinking water
NO996166L (en) Procedures for the treatment of odluor

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application